At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
JUNS Jupiter Neurosciences
Trading 10-12 09:42:32 EDT
2.85
+0.00
0.00%
High2.89Low2.77Vol8.15K
Open2.89D1 Closing2.85Amplitude4.21%
Mkt Cap3.76MTradable Cap3.13MTotal Shares1.32M
T/O23.17KT/O Rate0.74%Tradable Shares1.10M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Jupiter Neurosciences Explores Strategic Options
MT Newswires Live  ·  10-06
Jupiter Neurosciences Explores Strategic Options
Jupiter Neurosciences announces exploration of strategic options
TIPRANKS  ·  10-06
Jupiter Neurosciences announces exploration of strategic options
Jupiter Neurosciences Doses First Patient in Phase 2a Parkinson’s Trial of Jotrol
Reuters  ·  10-06
Jupiter Neurosciences Doses First Patient in Phase 2a Parkinson’s Trial of Jotrol
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a Reset Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
THOMSON REUTERS  ·  10-06
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a Reset Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Jupiter Neurosciences - Initiates Formal Process to Explore Strategic Options
THOMSON REUTERS  ·  10-06
Jupiter Neurosciences - Initiates Formal Process to Explore Strategic Options
Jupiter Neurosciences files to sell 132,867 shares of common stock for holders
TIPRANKS  ·  09-25
Jupiter Neurosciences files to sell 132,867 shares of common stock for holders
Jupiter Neurosciences Lowers Stockholder Meeting Quorum Requirement to One-Third of Voting Power
Reuters  ·  09-03
Jupiter Neurosciences Lowers Stockholder Meeting Quorum Requirement to One-Third of Voting Power
Stocks to Watch: Jupiter Neurosciences, Cyabra, Pinterest
Dow Jones  ·  08-29
Stocks to Watch: Jupiter Neurosciences, Cyabra, Pinterest
Jupiter Neurosciences Faces Nasdaq Delisting Risk Despite Compliance
TIPRANKS  ·  08-29
Jupiter Neurosciences Faces Nasdaq Delisting Risk Despite Compliance
Jupiter Neurosciences Faces NASDAQ Delisting After Market Value Falls Below $35 Million Threshold
Reuters  ·  08-29
Jupiter Neurosciences Faces NASDAQ Delisting After Market Value Falls Below $35 Million Threshold
Jupiter Neurosciences Gains Relief from Insider Debt Forgiveness
TIPRANKS  ·  08-27
Jupiter Neurosciences Gains Relief from Insider Debt Forgiveness
Jupiter Neurosciences Executives Forgive $875,315 in Accrued Unpaid Compensation
Reuters  ·  08-27
Jupiter Neurosciences Executives Forgive $875,315 in Accrued Unpaid Compensation
Top Premarket Decliners
MT Newswires Live  ·  08-25
Top Premarket Decliners
Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing
TIPRANKS  ·  08-25
Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing
Jupiter Neurosciences Says $2 Million Stock Sale Lifts Equity Above NASDAQ Minimum Listing Threshold
Reuters  ·  08-25
Jupiter Neurosciences Says $2 Million Stock Sale Lifts Equity Above NASDAQ Minimum Listing Threshold
US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada
MT Newswires Live  ·  08-22
US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?
TIPRANKS  ·  08-22
Why Is Penny Stock Jupiter Neurosciences (JUNS) Up Today?
Jupiter Neurosciences Prices USD 2 Million Registered Direct Offering of 307,692 Shares
Reuters  ·  08-22
Jupiter Neurosciences Prices USD 2 Million Registered Direct Offering of 307,692 Shares
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
THOMSON REUTERS  ·  08-22
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
NASDAQ Trade Halt Volatility Trading Pause at 10:02 Am
Reuters  ·  08-21
NASDAQ Trade Halt Volatility Trading Pause at 10:02 Am

Introduction

Company Name.
Jupiter Neurosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Jupiter Neurosciences, Inc. was incorporated in Delaware in January 2016. The company is a clinical-stage R&D company focused on developing treatments for neuroinflammation using its proprietary resveratrol formulation, JOTROL. Its primary therapeutic target is Parkinson's disease, for which it plans to conduct a Phase IIa clinical trial, and it has launched a consumer-facing product line called Nugevia focused on longevity and wellness.
Issue price:
--